Clinical trials: Liraglutide
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01507285
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type II
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of >…
- Trial name
- NCT01654120
- Testing
- Liraglutide, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mountain Diabetes and Endocrine Center
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
Congestive Heart Failure, Type 2 Diabetes Mellitus
Liraglutide and Heart Failure in Type 2 Diabetes
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with insulinotropic properties. Apart from the glycemic actions, cardiovascular effects by GLP-1 have recently been reviewed.
- Trial name
- NCT01425580
- Testing
- liraglutide, glimepiride, Metformin
- Where
- 2 sites in Sweden
- Volunteers
- 62 people
- Sponsor
- Thomas Nystrom
Diabetes, Diabetes Mellitus, Type 2
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
This study is conducted in Europe. The intention of this health service research study is to obtain data from daily routine to evaluate the quality of life and the costs of the disease for patients with type 2 diabetes mellitus.
- Trial name
- NCT01484262
- Testing
- liraglutide, insulin
- Where
- Germany
- Volunteers
- 1,344 people
- Sponsor
- Novo Nordisk A/S
Obesity
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
- Trial name
- NCT03041792
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics
This trial is conducted in Europe. The aim of this trial is to investigate whether a new compound, liraglutide, reduces the level of lipids (fat), including cholesterol, in the blood of type 2 diabetics, following a meal with…
- Trial name
- NCT00993304
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function
This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees…
- Trial name
- NCT01508806
- Testing
- liraglutide
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on…
- Trial name
- NCT02964247
- Testing
- liraglutide
- Where
- 82 sites in United States, Brazil and 5 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential.
- Trial name
- Liratime (NCT01499108)
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Peter Rossing
Obesity
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight.
- Trial name
- NCT04775082
- Testing
- Liraglutide
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 78 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obese Adults
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
- Trial name
- NCT07301437
- Testing
- liraglutide monotherapy, liraglutide combined with orlistat
- Volunteers
- 120 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Diabetes Mellitus
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
- Trial name
- NCT02231658
- Testing
- Liraglutide, Lixisenatide
- Where
- 2 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 2 Treated With Insulin
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.
- Trial name
- NCT05767255
- Testing
- insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart
- Where
- Colombia
- Volunteers
- 66 people
- Sponsor
- Hospital Universitario San Ignacio
Obesity, Weight Change, Body
Life Style Modification Medical and Surgical Management in Patients With Obesity
In this is an observational study, obese patients that administed and followed in endocrinology clinic of Marmara University Medical school hospital will follow for clinical and laboratory parameters prospectively for 5 years
- Conditions
- Obesity, Weight Change, Body, Obesity; Endocrine, Obesity, Metabolically Benign
- Trial name
- NCT04417582
- Testing
- bariatric surgey
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Marmara University
Diabetes, Healthy
Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations.
- Trial name
- NCT01319240
- Testing
- insulin degludec, insulin degludec/liraglutide, liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S